JP2020504707A5 - - Google Patents

Download PDF

Info

Publication number
JP2020504707A5
JP2020504707A5 JP2019523587A JP2019523587A JP2020504707A5 JP 2020504707 A5 JP2020504707 A5 JP 2020504707A5 JP 2019523587 A JP2019523587 A JP 2019523587A JP 2019523587 A JP2019523587 A JP 2019523587A JP 2020504707 A5 JP2020504707 A5 JP 2020504707A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
alkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019523587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504707A (ja
JP7042547B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/061868 external-priority patent/WO2018093947A1/en
Publication of JP2020504707A publication Critical patent/JP2020504707A/ja
Publication of JP2020504707A5 publication Critical patent/JP2020504707A5/ja
Application granted granted Critical
Publication of JP7042547B2 publication Critical patent/JP7042547B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019523587A 2016-11-16 2017-11-15 Magl阻害剤 Expired - Fee Related JP7042547B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423099P 2016-11-16 2016-11-16
US62/423,099 2016-11-16
PCT/US2017/061868 WO2018093947A1 (en) 2016-11-16 2017-11-15 Magl inhibitors

Publications (3)

Publication Number Publication Date
JP2020504707A JP2020504707A (ja) 2020-02-13
JP2020504707A5 true JP2020504707A5 (enExample) 2021-02-04
JP7042547B2 JP7042547B2 (ja) 2022-03-28

Family

ID=62106678

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019523587A Expired - Fee Related JP7042547B2 (ja) 2016-11-16 2017-11-15 Magl阻害剤

Country Status (29)

Country Link
US (1) US10093635B2 (enExample)
EP (1) EP3541821A4 (enExample)
JP (1) JP7042547B2 (enExample)
KR (1) KR20190077544A (enExample)
CN (1) CN110267963B (enExample)
AR (1) AR110089A1 (enExample)
AU (1) AU2017361251B2 (enExample)
BR (1) BR112019009994A2 (enExample)
CA (1) CA3043615A1 (enExample)
CL (1) CL2019001339A1 (enExample)
CO (1) CO2019005059A2 (enExample)
CR (1) CR20190241A (enExample)
DO (1) DOP2019000122A (enExample)
EA (1) EA038090B1 (enExample)
EC (1) ECSP19035077A (enExample)
GE (2) GEP20237470B (enExample)
IL (1) IL266523B (enExample)
JO (1) JOP20190106A1 (enExample)
MA (1) MA46857A (enExample)
MX (1) MX391117B (enExample)
NI (1) NI201900051A (enExample)
PE (1) PE20191144A1 (enExample)
PH (1) PH12019501097A1 (enExample)
RU (1) RU2754536C1 (enExample)
TN (1) TN2019000153A1 (enExample)
TW (1) TWI756299B (enExample)
UA (1) UA124542C2 (enExample)
WO (1) WO2018093947A1 (enExample)
ZA (1) ZA201903100B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000198T1 (it) 2012-01-06 2020-07-08 Scripps Research Inst Composti di carbammato e metodi di produzione e di utilizzo degli stessi
MX2017014344A (es) 2015-05-11 2018-04-11 Abide Therapeutics Inc Metodos para el tratamiento de la inflacion o el dolor neuropatico.
US10899737B2 (en) 2016-09-19 2021-01-26 Lundbeck La Jolla Research Center, Inc. Piperazine carbamates and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
EP3541807B1 (en) 2016-11-16 2021-09-29 H. Lundbeck A/S A crystalline form of a magl inhibitor
CN110290791A (zh) 2016-11-16 2019-09-27 灵北拉荷亚研究中心公司 药物制剂
RS64006B1 (sr) 2017-05-23 2023-03-31 H Lundbeck As Pirazol magl inhibitori
MA50041A (fr) 2017-08-29 2020-07-08 Lundbeck La Jolla Research Center Inc Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
SG11202011228TA (en) * 2018-05-15 2020-12-30 Lundbeck La Jolla Research Center Inc Magl inhibitors
MA54827A (fr) * 2019-01-25 2022-05-04 H Lundbeck As Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl
AU2020383502A1 (en) * 2019-11-15 2022-06-30 H. Lundbeck A/S Crystalline forms of a MAGL inhibitor
IT202000007150A1 (it) * 2020-04-03 2021-10-03 Univ Pisa Inibitori di monoacilglicerolo lipasi (magl)
WO2021214550A1 (en) 2020-04-21 2021-10-28 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
WO2023130023A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
US12378219B2 (en) 2022-05-04 2025-08-05 H. Lundbeck A/S Crystalline forms of a MAGL inhibitor

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593586A (enExample) 1967-10-17 1970-06-01
JPS6183073A (ja) 1984-10-01 1986-04-26 Oki Electric Ind Co Ltd 印字装置の用紙送り方法
WO1989011794A1 (fr) 1988-06-07 1989-12-14 Rikagaku Kenkyusho Inhibiteur de la croissance de plantes
EP0619804B1 (en) 1991-11-27 1996-05-22 E.I. Du Pont De Nemours And Company Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives
EP0736047B1 (en) 1993-12-22 1998-03-04 Shell Internationale Researchmaatschappij B.V. Process for preparing carbamates
WO1997018196A1 (en) 1995-11-15 1997-05-22 Zeneca Limited Herbicidal substituted pyrazole compounds
AU3440597A (en) 1996-07-02 1998-01-21 Novartis Ag N-phenylimino heterocyclic derivatives and their use as herbicides
RU2167150C2 (ru) 1998-03-25 2001-05-20 Фокин Александр Васильевич Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
AU7856600A (en) 1999-10-04 2001-05-10 University Of Medicine And Dentistry Of New Jersey Novel carbamates and ureas
EP1201298A1 (en) 2000-10-24 2002-05-02 Urea Casale S.A. Carbamate condensation unit
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
AU2003300702A1 (en) 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research Process for preparing carbamates
KR20070026382A (ko) 2004-02-18 2007-03-08 아스트라제네카 아베 아세틸린성 피페라진 화합물 및 대사성 글루타메이트수용체 길항제로서 이들의 용도
EP1831218A2 (en) 2004-12-23 2007-09-12 F.Hoffmann-La Roche Ag Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
ME02929B (me) 2004-12-30 2018-04-20 Janssen Pharmaceutica Nv DERIVATIVI FENILAMIDA 4-(BENZIL)-PIPERAZIN-1-KARBOKSILNE KISELINE l SLIĆNA JEDINJENJA KAO MODULATORI HIDROLAZE AMIDA MASNIH KISELINA (FAAH) ZA LEĆENJE ANKSIOZNOSTI, BOLA l OSTALIH STANJA
EP1948630A2 (en) * 2005-11-05 2008-07-30 AstraZeneca AB Novel compounds
JP2009523729A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス,インコーポレーテッド C型肝炎の治療方法
EP2114941B1 (en) 2006-12-22 2015-03-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
CN101711154A (zh) 2007-02-26 2010-05-19 科森生物科学公司 氨基甲酸酯化合物
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
JP2011528368A (ja) 2008-07-16 2011-11-17 シェーリング コーポレイション 二環式ヘテロ環誘導体およびgpcrモジュレーターとしてのその使用
CA2743861A1 (en) 2008-11-14 2010-05-20 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
WO2010111050A1 (en) 2009-03-23 2010-09-30 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
RU2011147181A (ru) * 2009-04-22 2013-05-27 Янссен Фармацевтика Нв Азетидинилдиамиды в качестве ингибиторов моноациглицерин-липазы
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
ES2433235T3 (es) 2009-11-03 2013-12-10 Bayer Intellectual Property Gmbh Fluorouretanos como aditivos en una formulación de fotopolímero
FR2960875B1 (fr) * 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
SMT202000198T1 (it) * 2012-01-06 2020-07-08 Scripps Research Inst Composti di carbammato e metodi di produzione e di utilizzo degli stessi
HUE038403T2 (hu) 2012-01-06 2018-10-29 Agios Pharmaceuticals Inc Terápiásan alkalmazható vegyületek és alkalmazási módszereik
MX2014011134A (es) 2012-03-19 2014-12-10 Abide Therapeutics Inc Compuestos de carbamato y preparacion y uso de los mismos.
JP2014005245A (ja) * 2012-06-26 2014-01-16 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体を含有する医薬組成物
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
WO2015003002A1 (en) 2013-07-03 2015-01-08 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
WO2016014975A2 (en) * 2014-07-25 2016-01-28 Northeastern University Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof
US9771341B2 (en) 2015-03-18 2017-09-26 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
US10899737B2 (en) * 2016-09-19 2021-01-26 Lundbeck La Jolla Research Center, Inc. Piperazine carbamates and methods of making and using same
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)

Similar Documents

Publication Publication Date Title
JP2020504707A5 (enExample)
JP2020500178A5 (enExample)
RU2019116512A (ru) Ингибиторы magl
JP2005526076A5 (enExample)
RU2448964C2 (ru) КАРБОЦИКЛИЧЕСКИЕ И ГЕТЕРОЦИКЛИЧЕСКИЕ АРИЛСУЛЬФОНЫ, ИХ ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, ОБЛАДАЮЩАЯ СВОЙСТВАМИ ИНГИБИТОРА γ-СЕКРЕТАЗЫ
JP2020522520A5 (enExample)
RU2006109600A (ru) N3-алкилированные бензимидазольные производные в качестве ингибиторов мек
JP2020530487A5 (enExample)
AR045609A1 (es) Derivados de malonamida
RU2019116514A (ru) Ингибиторы magl
RU2019115784A (ru) Ингибиторы magl
JP2016533397A5 (enExample)
JP2014520887A5 (enExample)
JP2020521767A5 (enExample)
PE20212253A1 (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd)
JP2016121196A5 (enExample)
JP2016534134A5 (enExample)
RU2012143212A (ru) Способ лечения артрита
JP2016514192A5 (enExample)
JP2021508318A5 (enExample)
JP2014526533A5 (enExample)
JP2020521766A5 (enExample)
JP2019535813A5 (enExample)
JP2016534984A5 (enExample)
JP2019532092A5 (enExample)